SCHEMBL1854412

SCHEMBL1854412

O=C(O)C(=O)N(Cc1ccccc1)Cc1ccc(-c2cccc(C(=O)NCC(c3ccccc3)c3ccccc3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.48
EPHX2 P34913 2/20 0.48
PRMT5 O14744 1/20 0.46
CFD P00746 1/20 0.45
PTGES O14684 1/20 0.44
SENP1 Q9P0U3 2/20 0.43
TACR1 P25103 1/20 0.43
ERN1 O75460 1/20 0.43
HDAC8 Q9BY41 1/20 0.42
MEP1B Q16820 1/20 0.41
CASR P41180 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
UTS2R Q9UKP6 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1854789 0.94 UTS2R (0.48) NR1H4EPHX2PRMT5UTS2R
SCHEMBL1853555 0.91 TACR1 (0.53) NR1H4EPHX2PRMT5TACR1
SCHEMBL1855533 0.91 GPR139 (0.43) NR1H4EPHX2PRMT5PTGESALDH1A1
SCHEMBL4315436 0.84 EPHX2 (0.44) NR1H4EPHX2PRMT5UTS2R
SCHEMBL5047432 0.83 NR1H4 (0.53) NR1H4EPHX2PRMT5CFDSENP1
SCHEMBL1855976 0.79 EPHX2 (0.55) NR1H4EPHX2CFDSENP1ERN1
SCHEMBL5044326 0.77 P2RX7 (0.49) NR1H4EPHX2PRMT5UTS2R
SCHEMBL6440695 0.77 ERN1 (0.49) NR1H4EPHX2ERN1KDM4EALDH1A1
SCHEMBL1855755 0.76 TMEM97 (0.51) EPHX2NPC1RAB9A
SCHEMBL1856432 0.76 F10 (0.47) KDM4EALDH1A1HPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1470102-B1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) MERCK SERONO SA (CH) 2011-05-25 EP claimed
EP-1732534-B1 USE OF METHYLENE AMIDE DERIVATIVES IN CARDIOVASCULAR DISORDERS SERONO LAB (CH) 2008-07-23 EP claimed
US-20070185118-A1 Use of methylene amide derivatives in cardiovascular disorders APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-08-09 US claimed
US-20050124656-A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) APPLIED RESEARCH SYSTEMS ARS (NL) 2005-06-09 US claimed
EP-1470102-B1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) MERCK SERONO SA (CH) 2011-05-25 EP disclosed
US-7592477-B2 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) LABORATOIRES SERONO SA (CH) 2009-09-22 US disclosed
US-20070185118-A1 Use of methylene amide derivatives in cardiovascular disorders APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2007-08-09 US disclosed
US-20050124656-A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) APPLIED RESEARCH SYSTEMS ARS (NL) 2005-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185118-A1 Use of methylene amide derivatives in cardiovascular disorders TNNI3, TNNT2, ADM2 NR1H4 510/4885EPHX2 495/4885PRMT5 15/4885
US-20050124656-A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) PTPRS, PTPA, PTPMT1 NR1H4 1543/4885EPHX2 2771/4885PRMT5 158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.